Skip to main content
SpringerLink
Log in

Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Thymidylate synthase (TS) is the enzyme target of 5-fluorouracil (FUra) that recent laboratory and clinical studies with folinic acid (calcium leucovorin) suggest may mediate important antitumor cytotoxicity. Measurement in carcinoma tissue of parameters related to TS inhibition by 5-fluorodeoxyuridylate (FdUMP), by analogy to hormone receptor analysis, should be useful to determine which patients should receive fluoropyrimidine drug therapy and to evaluate folinic acid requirements. Folinic acid is metabolized to 5,10-methylenetetrahydropteroylglutamine (CH2FH4), which must be present in large excess to effect desired levels of maximal inhibition of TS, by promoting formation and stabilization of TS-FdUMP-CH2FH4 ternary complexes. In patients with metastatic disease, serial biopsies of tumor and normal tissues for studies of pharmacodynamic responses to test-dose FUra or folinic acid are shown to be easily added to routine intraoperative management. A suitable methodologic approach is described and examples given of assays of free TS, FdUMP, dUMP, and CH2FH4 levels after FUra or folinic acid, that may be useful in future studies aimed at improving the cost-effectiveness of FUra-folinic acid combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

TS:

Thymidylate Synthase (EC 2.1.1.45)

FUra:

5-fluorouracil

FdUMP:

5-fluorodeoxyuridylate

dUMP:

deoxyuridylate

CH2FH4 :

5,10-methylenetetrahydropteroylglutamate

5-CH3FH4 :

5-methyltetrahydropteroylglutamate

References

  1. Schornagel JH, Leyva A, Pinedo HM: Is there a role for thymidine in cancer chemotherapy? Cancer Treat Rep 9:331–352, 1982

    Google Scholar 

  2. van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM: Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70:745–750, 1986

    Google Scholar 

  3. Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE: Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res 40:1885–1889, 1980

    Google Scholar 

  4. Houghton JA, Houghton PJ: Combinations of 5-FU, hypoxanthine, and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. Cancer Treat Rep 66:1201–1206, 1982

    Google Scholar 

  5. Allegra CJ, Jolivet J, Drake JC, Chabner BA: Folate and antifolate effects on the thymidylate synthetase-FdUMP complex. In: Bruckner H, Rustum YM (eds), The Current Status of 5-Fluorouracil-Leucovorin Calcium Combination. John Wiley and Sons, 1984, pp 41–45

  6. Pogolotti AL Jr, Danenberg PV, Santi DV: Kinetics and mechanism of interaction of 10-propargyl-5,8-dideazafolate with thymidylate synthase. J Med Chem 29:478–482, 1986

    Google Scholar 

  7. Anukarahenonta T, Holstege A, Keppler DOR: Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonoacetyl)-L-aspartate. Eur J Cancer 16:1171–1180, 1980

    Google Scholar 

  8. Cadman E, Benz C, Heimer R, O'Shaughnessy J: Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity. Biochem Pharmacol 30:2469–2472, 1981

    Google Scholar 

  9. Ardalan B, Arakawa M, Villacorte D, Jayaram H, Cooney DA: Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenocarcinomas in vivo. Biochem Pharmacol 31:1509–1513, 1982

    Google Scholar 

  10. Zhen Y-S, Lui MS, Weber G: Effects of acivicin and dipyridamole on hepatoma 3924A cells. Cancer Res 43:1616–1619, 1983

    Google Scholar 

  11. Mekras JA, Boothman DA, Perez LM, Greer S: Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidine deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res 44:2551–2560, 1984

    Google Scholar 

  12. Kessel D, Hall TC: Effects of persantin on deoxycytidine transport by murine leukemia cells. Biochem Biophys Acta 217:88–94, 1970

    Google Scholar 

  13. Grem JL, Fischer PH: Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45:2967–2972, 1985

    Google Scholar 

  14. Darnowski JW, Handschumacher RE: Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res 45:5364–5368, 1985

    Google Scholar 

  15. Cadman E, Heimer R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 205:1135–1137, 1979

    Google Scholar 

  16. Evans RM, Laskin RD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288–3295, 1981

    Google Scholar 

  17. Kessel D, Hall TC: Influence of ribose donors on the action of 5-fluorouracil. Cancer Res 29:1749–1754, 1969

    Google Scholar 

  18. Ullman B, Lee M, Martin DW Jr, Santi DV: Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc. Natl. Acad. Sci. USA 75:980–983, 1978

    Google Scholar 

  19. Houghton JA, Schmidt C, Houghton PJ: The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol 18:347–354, 1982

    Google Scholar 

  20. Houghton JA, Houghton PJ: Basis for the interaction of 5-fluorouracil and leucovorin in colon adenocarcinoma. In: Bruckner HW, Rustum YM (eds), The Current Status of 5-Fluorouracil-Leucovorin Calcium Combination. John Wiley and Sons, 1984, pp 23–32

  21. Yin, M-B, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 23:190–197, 1982

    Google Scholar 

  22. Hakala MT: Basis for the effect of leucovorin on the activity and site of action of 5-fluorouracil in human cells. In: Bruckner HW, Rustum YM (eds). The Current Status of 5-Fluorouracil-Leucovorin Calcium Combination. John Wiley and Sons, 1984, pp 33–39

  23. Lockshin A, Danenberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30:247–257, 1981

    Google Scholar 

  24. Scanlon KJ, NeeDels C, Lu Y, Lin C, Newman E, Leong L, Mini E: Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumors. Proc Amer Assoc Cancer Res 27:291, 1986

    Google Scholar 

  25. Waxman S, Bruckner H: The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione, and αtocopherol. Eur J Cancer Clin Oncol 18:685–692, 1982

    Google Scholar 

  26. Block JB, Chlebowski RT, Dietrich M: Warfarin and Vitamin K effects on tumor growth and on pyrimidine biosynthetic pathway in vitro. Proc Amer Assoc Cancer Res 22:224, 1981

    Google Scholar 

  27. Tryfiates GP: Activation and protection from 5-fluorodeoxyuridylate inactivation of mammalian thymidylate synthetase by pyridoxal 5′-phosphate. Enzyme 25:356–360, 1980

    Google Scholar 

  28. Iigo M, Hoshi A: Effect of guanosine on antitumor activity of fluorinated pyrimidines against P388 leukemia. Cancer Chemother Pharmacol 13:86–90, 1984

    Google Scholar 

  29. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorouridylate. Biochemistry 13:471–480, 1974

    Google Scholar 

  30. Danenberg PV, Langenbach RJ, Heidelberger C: Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides. Biochemistry 13:926–933, 1974

    Google Scholar 

  31. Heidelberger C, Danenberg PV, Moran RG: Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 54:58–119, 1983

    Google Scholar 

  32. Spears CP, Hayes AA, Danenberg PV, Shahinian AH, Frösing R, and Gustavsson BG: Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation. Biochem Pharmacol (in press, 1989)

  33. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In vivo kinetics of thymidylate synthetase inhibition in FUra-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42:450–456, 1982

    CAS  PubMed  Google Scholar 

  34. Machover D, Schwartzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R, Mathe G: Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66:1803–1807, 1982

    Google Scholar 

  35. Petrelli N, Herrera L, Stulc J, Burke P, Rustum Y, Mittelman A: A phase III study of 5-fluorouracil (5-FU) versus 5-FU + methotrexate versus 5-FU + high dose leucovorin in metastatic colorectal adenocarcinoma. (Abstr) Proc Am Soc Clin Oncol 5:78, 1986

    Google Scholar 

  36. Bertrand M, Dorochow JH, Multhauf P, Blayney DW, Carr BI, Cecchi G, Goldberg D, Leong L, Margolin K, Metter G, Staples R: High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancers: a phase I–II study. J Clin Oncol 4:1058–1061, 1986

    Google Scholar 

  37. Bruckner HW, Crown J, McKenna A, Hart R: High dose intermittent leucovorin with 5-fluorouracil for unknown primary and atypical pancreatic cancer. (Abstr) Proc Amer Assoc Cancer Res 27:183, 1986

    Google Scholar 

  38. Zakem M, Hines JD, Adelstein DJ, Rustum YM: High-dose leucovorin and 5-fluorouracil in refractory and relapsed colo-rectal carcinoma. (Abstr) Proc Amer Soc Clin Oncol 5:81, 1986

    Google Scholar 

  39. Erlichman C, Fine S, Wong A, Elhakim T: A comparison of 5-fluorouracil (5-FU) and folinic acid versus 5-FU in metastatic colorectal carcinoma. (Abstr) Proc Amer Soc Clin Oncol 5:82, 1986

    Google Scholar 

  40. Kaiser L, Fine S, Erlichman C: Sequential methotrexate-fluorouracil: the role of leucovorin in improving tumor response. J Clin Oncol 4:1280, 1986

    Google Scholar 

  41. Moran RG, Spears C, Heidelberger C: Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci USA 76:1456–1460, 1979

    Google Scholar 

  42. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV: Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given bolus intravenous 5-fluorouracil. Cancer Res 44:4144–4150, 1984

    Google Scholar 

  43. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA: Mechanism of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48:5894–5900, 1988

    Google Scholar 

  44. Priest DG, Alford CW, Batson KK, Doig MT: A centrifugal column assay for thymidylate synthetase using the active site titrant 5-fluoro-2′-deoxyuridylate. Anal Biochem 103:51–54, 1980

    Google Scholar 

  45. Priest DG, Veronee CD, Mangum M, Bednarek JM, Doig MT: Comparison of folypolyglutamate hydrolases of mouse liver, kidney, muscle, and brain. Mol Cell Biochem 43:81–87, 1982

    Google Scholar 

  46. Sur P, Doig MT, Priest DG: Response of methylenetetrahydrofolate levels to methotrexate in Krebs ascites cells. Biochem J 216:295–298, 1983

    Google Scholar 

  47. Kesavan V, Sur P, Doig MT, Scanlon KJ, Priest DG: Effects of methotrexate on folates in Krebs ascites and L1210 murine leukemia cells. Cancer Lett 30:55–59, 1986

    Google Scholar 

  48. Sharma RK, Kisliuk RL: Quenching of thymidylate synthetase fluorescence by substrate analogs. Biochem Biophys Res Commun 64:648–655, 1975

    Google Scholar 

  49. Washtien WL, Santi DV: Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Cancer Res 39:3397–3404, 1979

    Google Scholar 

  50. Danenberg PV, Lockshin A: Tight-binding complexes of thymidylate synthetase, folate analogs and deoxyribonucleotides. Adv Enz Regul 20:99–110, 1982

    Google Scholar 

  51. Trave F, Frank C, Petrelli N, Herrera L, Mittelman A, Rustum Y: Pharmacokinetics of folates in patients with colorectal carcinoma. (Abstr) Proc Amer Assoc Cancer Res 27:171, 1986

    Google Scholar 

  52. Houghton JA, Rodparvar S, Torrance PM, Williams LG, Houghton PJ: Determination of thymidylate synthase activity in colon tumor after treatment with 5-fluorouracil. Biochem Pharmacol 36:1285–1289, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Southern California Comprehensive Cancer Center, 90033, Los Angeles, CA, USA

    Colin Paul Spears

  2. Östra Hospital, University of Göteborg, Sweden

    Bengt G. Gustavsson & Roland Frösing

Authors
  1. Colin Paul Spears
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bengt G. Gustavsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roland Frösing
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spears, C.P., Gustavsson, B.G. & Frösing, R. Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration. Invest New Drugs 7, 27–36 (1989). https://doi.org/10.1007/BF00178189

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00178189

Key words

Search

Navigation